Helicobacter pylori (H. pylori) is one of the main causes of peptic ulcer disease and gastric cancer. The overuse of antibiotics leads to bacterial drug resistance and disruption to the gut microbiome. Herein, a nanoparticle (TA-FeHMSN@Amox) was developed, comprising amoxicillin (Amox)-loaded iron-engineered hollow mesoporous silica as the core and a metal–polyphenol shell formed by tannic acid (TA) and Fe³⁺. In acidic stomach conditions, TA-FeHMSN@Amox generates bactericidal ·OH through Fenton/Fenton-like reactions of the degraded product Fe²⁺ and hydrogen peroxide (H₂O₂) at the infection site, achieving chemodynamic therapy (CDT). Moreover, released amoxicillin enhances therapeutic efficacy by impeding the self-repair of the bacterial cell wall damaged by CDT, overcoming the limitations of ineffective CDT under conditions lacking sufficient acidity and H₂O₂. The acidity-responsive CDT combined with reduced antibiotic usage ensures superior in vivo therapeutic efficacy and biocompatibility with intestinal flora, providing a highly potent strategy for treating H. pylori infections in the dynamic stomach environment.

中文翻译：

---

抗生素增强化学动力学疗法治疗动态胃环境中幽门螺杆菌感染


幽门螺杆菌 （H. pylori） 是消化性溃疡病和胃癌的主要原因之一。抗生素的过度使用会导致细菌耐药性和肠道微生物组的破坏。在此，开发了一种纳米颗粒 （TA-FeHMSN@Amox），由阿莫西林 （Amox） 负载的铁工程空心介孔二氧化硅为核心，由单宁酸 （TA） 和 Fe³⁺ 形成金属-多酚壳。在酸性胃条件下，TA-FeHMSN@Amox 会产生杀菌剂 ·OH 通过降解产物 Fe²⁺ 和过氧化氢 （H₂O₂） 在感染部位的 Fenton/Fenton 样反应，实现化学动力学疗法 （CDT）。此外，释放的阿莫西林通过阻碍 CDT 损伤的细菌细胞壁的自我修复来增强治疗效果，克服了在缺乏足够酸度和 H₂O₂ 的条件下无效 CDT 的局限性。酸性反应性 CDT 与减少抗生素使用相结合，确保了卓越的体内治疗效果和与肠道菌群的生物相容性，为在动态胃环境中治疗幽门螺杆菌感染提供了高效的策略。